Glomerular Diseases: 2026 Update
Glomerular Diseases: 2026 Update
October 21, 2026 | 07:00 AM - 06:00 PM
Location: Mile High Ballroom 2, Convention Center
Session Description
This comprehensive program highlights exciting new developments in glomerular disease mechanisms, diagnostic tools, and novel therapies. Expert clinicians and researchers discuss major mechanistic and clinical trial breakthroughs and their relevance to patient care through focused didactics, case studies, and audience interaction.
The program explores all major glomerular diseases, including IgA nephropathy, membranous glomerulopathy, ANCA-associated vasculitis, lupus nephritis, focal segmental glomerulosclerosis, and amyloidosis, as well as special-interest topics such as C3 glomerulopathy, glomerular diseases during pregnancy, and nonimmunosuppressive therapies for reducing proteinuria. Two engaging clinicopathologic case conferences challenge panelists as they collaborate to solve difficult cases.
Participants gain a better understanding of the major glomerular diseases and become more confident in managing medically complex patients.
ASN designates this live activity for a maximum of 8.25 AMA PRA Category 1 CreditsTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Session Objectives
Upon completion of this program, the participant will be able to: 1) summarize treatment options, both immunosuppressive and nonimmunosuppressive, for primary and secondary glomerular diseases; 2) describe high-risk clinicopathologic features of glomerular diseases that indicate a worse prognosis; 3) analyze recent clinical trial results and their implications for patient care; and 4) discuss differential diagnoses for nephrotic and nephritic processes.
Support is provided by an educational grant from Vera Therapeutics, Inc.
Moderators
Presentations
-
Check-In and Continental Breakfast
-
Welcome and Introduction
-
Evaluation and Management of Patients with ANCA-Positive Serologies
-
IgA Nephropathy: How Patient Factors Inform Therapeutic Plans
-
Novel Treatment Options for C3 Glomerulopathy and Membranoproliferative Glomerulonephritis
-
Break
-
Advances in B-Cell-Targeted Therapy for Lupus Nephritis
-
Clinicopathologic Conference 1: Nephritic Syndromes
- Jonathan Barratt, MBChB, PhD
- Pietro A. Canetta, MD, MS, FASN
- Jean Hou, MD
- Shaun W. Jackson, MD, MBChB
- Koyal Jain, MD, MEd, FASN, MPH
- Matt G. Sampson, MD
- Joshua M. Thurman, MD, FASN
-
Lunch (on your own)
-
Four Pillars in the Management of Glomerular Diseases
-
Diagnosis and Management of Glomerular Diseases During Pregnancy
-
Renal Amyloidosis: Updates in Typing, Classification, and Treatment Recommendations
-
Break
-
Genetics of Focal Segmental Glomerulosclerosis: The Podocyte and Beyond
-
APOL1-Mediated Kidney Disease: Update on Pathogenesis and Investigational Therapies
-
Membranous Nephropathy: Novel Target Antigen Discovery and Therapeutic Implications
-
Clinicopathologic Conference 2: Nephrotic Syndromes
- Laith Al-Rabadi, MD
- Yelena Drexler, MD, MS, FASN
- Leal C. Herlitz, MD
- Shaun W. Jackson, MD, MBChB
- Nelson Leung, MD
- Andrea L. Oliverio, MD, MS, MSc
- Matt G. Sampson, MD